IP Library Granted Patent US 8,772,471
Granted Patent B2
US 8,772,471 · App. 12/524,536 · Granted Jul 8, 2014

Targeted delivery of siRNA

Inventors: Premlata Shankar (El Paso, TX); Sang-Kyung Lee (Seoul, KR); Manjunath Narasimhaswamy (El Paso, TX); Priti Kumar (Hamden, CT); Haoquan Wu (Jamaica Plain, MA); Hong-Seok Ban (Seoul, KR)
Assignees: Industry-University Cooperation Foundation Hanyang University; Immune Disease Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,471
App. No.
12/524,536
Granted
Jul 8, 2014
Kind
B2
Abstract

The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell.

Claims (6)

1. A composition comprising a targeting moiety associated with a binding moiety, wherein a double stranded RNA segment is associated with the binding moiety, wherein the targeting moiety is an antibody or antigen binding fragment thereof which binds to CD7, and the binding moiety is an oligo-9-peptide (9R), wherein the oligo-9-peptide comprises 9 consecutive arginines.

2. The composition of claim 1 , wherein the targeting moiety specifically binds to a cell-surface antigen on a target cell, wherein the cell surface antigen internalizes when the targeting moiety binds the cell surface antigen.

3. The composition of claim 2 , wherein the target cell is a T-cell.

4. The composition of claim 1 , wherein the targeting moiety and binding moiety are comprised as a fusion protein, wherein the binding moiety is fused to the carboxy portion of the targeting moiety.

5. The composition of claim 2 , wherein the cell is selected from the group consisting of a cultured cell, cell that is part of an organ, a cell that is part of a subject and an embryonic stem cell.

6. The composition of claim 5 , wherein the subject is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2010
From: SHANKAR, PREMLATA; NARASIMHASWAMY, MANJUNATH; KUMAR, PRITI; WU, HAOQUAN
To: IMMUNE DISEASE INSTITUTE
Reel/Frame 024284/0851 →
Continuity (2)
Provisional Application 60897720 · Jan 26, 2007
Related Publication 20100209440A1 · Aug 19, 2010